Across TCGA pan-cancer cohorts, SVIP mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SVIP data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SVIP mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SVIP expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

HNSC, LUAD, and GBM are the cancer types where SVIP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	All	0.900	0.570	.007	9	view →
LUAD	OS	Tertile	III,IV	0.800	1.000	.037	5	view →
GBM	DFS	Median	All	0.839	0.656	.027	3	view →
LSCC	OS	Median	All	1.000	0.813	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: SVIP tumor-vs-normal RNA expression · all SVIP data types